Compare AMBA & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMBA | RCUS |
|---|---|---|
| Founded | 2004 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.8B |
| IPO Year | N/A | 2018 |
| Metric | AMBA | RCUS |
|---|---|---|
| Price | $68.98 | $22.00 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 9 |
| Target Price | ★ $97.25 | $28.89 |
| AVG Volume (30 Days) | 1.1M | ★ 1.6M |
| Earning Date | 02-25-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $373,850,000.00 | $240,000,000.00 |
| Revenue This Year | $39.65 | N/A |
| Revenue Next Year | $9.86 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 48.08 | N/A |
| 52 Week Low | $38.86 | $6.50 |
| 52 Week High | $96.69 | $26.40 |
| Indicator | AMBA | RCUS |
|---|---|---|
| Relative Strength Index (RSI) | 44.96 | 47.16 |
| Support Level | $64.00 | $20.59 |
| Resistance Level | $69.05 | $23.40 |
| Average True Range (ATR) | 3.29 | 1.39 |
| MACD | -0.33 | -0.07 |
| Stochastic Oscillator | 29.05 | 32.38 |
Ambarella Inc is a developer of semiconductor processing solutions for high-definition video capture, sharing, and display. The firm's solutions are sold to original design manufacturers and original equipment manufacturers to be designed for use in infrastructure broadcast encoders, wearable device cameras, automotive cameras, security cameras, consumer cameras, and industrial and robotic applications. The company's system-on-a-chip designs, based on its proprietary technology platform, are configurable to applications in various end markets. Geographical presence in Taiwan, Asia Pacific, Europe, North America, and the United States. The firm derives the majority of its revenue from Taiwan.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.